Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07305883

Comparison of Intranasal Ketorolac and Intranasal Ketamine in Digital Nerve Block Pain

Intranasal Ketorolac Effectiveness In Comparison To Intranasal Ketamine for Digital Nerve Block Pain; A Randomized, Double Blind Trial

Status
Not Yet Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
64 (estimated)
Sponsor
Tehran University of Medical Sciences · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This study aims to compare the analgesic effectiveness and side effects of intranasal ketorolac versus intranasal ketamine for reducing pain prior to digital nerve block procedures in patients with finger injuries in emergency department.

Detailed description

Acute pain management in emergency department during painful procedures such as digital nerve block is crucial to be implemented in a rapid-onset method. Ketorolac, a potent NSAID, and ketamine, an NMDA receptor antagonist with analgesic effects, have both been shown to be effective and fast-onset when administered intranasally. This non-invasive method of Ketorolac is not supported by sufficient evidences in such clinical scenarios. Addressing this research gap may lead to reduced pain and complications, as well as higher patient satisfaction, contributing the development of novel pre-procedural analgesic strategies in emergency settings. Participants will be randomly assigned to receive either 30 mg intranasal ketorolac or 50 mg intranasal ketamine, administered 5 minutes prior to the digital nerve block. Pain will be assessed using the Numeric Rating Scale (NRS). Secondary endpoints include nasal irritation, side effects, and patient satisfaction.

Conditions

Interventions

TypeNameDescription
DRUGIntranasal Ketorolac Tromethamine30 mg ketorolac will be administered intranasally using mucosal atomizer. Half dose (0.5 cc) in each nostril, Given 5 minutes before digital nerve block.
DRUGIntranasal ketamine50 mg ketamine will be administered intranasally using mucosal atomizer,. Half dose (0.5cc) in each nostril, Given 5 minutes before digital nerve block

Timeline

Start date
2025-12-28
Primary completion
2026-06-20
Completion
2026-08-01
First posted
2025-12-26
Last updated
2025-12-26

Source: ClinicalTrials.gov record NCT07305883. Inclusion in this directory is not an endorsement.